News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
50,149 Results
Type
Article (2058)
Company Profile (8)
Press Release (48085)
Section
Business (21845)
Career Advice (65)
Deals (2960)
Drug Delivery (4)
Drug Development (6440)
Employer Resources (11)
FDA (1175)
Job Trends (1319)
News (29690)
Policy (1769)
Tag
2027 Pharm Country Standard (2)
Academia (143)
Accelerated approval (15)
ADA (5)
Allergies (17)
Alliances (1817)
ALS (13)
Alzheimer's disease (126)
Antibody-drug conjugate (ADC) (80)
Approvals (1350)
Artificial intelligence (40)
ASCO (48)
Autoimmune disease (48)
Automation (4)
Bankruptcy (11)
Best Places to Work (1231)
BIO (1)
Biosimilars (35)
BioSpace Insights (7)
Biotechnology (5)
Bladder cancer (56)
Brain cancer (4)
Breast cancer (138)
Cancer (916)
Cardiovascular disease (68)
Career advice (60)
Career pathing (3)
CAR-T (25)
CDC (1)
CDMO (5)
Cell therapy (59)
Cervical cancer (9)
Clinical research (6621)
Collaboration (129)
Commercialization (1)
Compensation (74)
Complete response letters (9)
COVID-19 (128)
CRISPR (8)
C-suite (51)
Cystic fibrosis (9)
Data (1308)
Denatured (1)
Depression (21)
Dermatology (28)
Diabetes (57)
Diagnostics (523)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (2)
Drug discovery (14)
Drug pricing (8)
Drug shortages (6)
Duchenne muscular dystrophy (34)
Earnings (19917)
Editorial (2)
Employer resources (9)
Events (5370)
Executive appointments (36)
FDA (1801)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (117)
Gene editing (19)
Generative AI (2)
Gene therapy (52)
GLP-1 (115)
Government (234)
Grass and pollen (1)
Guidances (212)
Healthcare (1437)
Hematology (24)
HIV (12)
Huntington's disease (7)
IgA nephropathy (26)
Immunology and inflammation (25)
Immuno-oncology (10)
Indications (42)
Infectious disease (152)
Inflammatory bowel disease (24)
Inflation Reduction Act (1)
Influenza (10)
Intellectual property (20)
Interviews (12)
IPO (2159)
IRA (1)
Job creations (168)
Job search strategy (49)
JPM (4)
Kidney cancer (6)
Kidney disease (6)
Labor market (14)
Layoffs (53)
Legal (231)
Liver cancer (16)
Longevity (1)
Lung cancer (154)
Lymphoma (106)
Management (4)
Manufacturing (77)
MASH (29)
Medical device (1233)
Medtech (1249)
Mergers & acquisitions (906)
Metabolic disorders (171)
mRNA (13)
Multiple sclerosis (46)
NASH (2)
Netherlands (3)
Neurodegenerative disease (40)
Neuropsychiatric disorders (11)
Neuroscience (314)
NextGen: Class of 2026 (349)
Non-profit (167)
Now hiring (3)
Obesity (86)
Opinion (14)
Ovarian cancer (56)
Pain (18)
Pancreatic cancer (21)
Parkinson's disease (34)
Patents (39)
Patient recruitment (33)
Peanut (7)
People (1538)
Peptides (1)
Pharmaceutical (1)
Pharmacy benefit managers (4)
Phase 1 (1424)
Phase 2 (2590)
Phase 3 (3062)
Pipeline (2351)
Policy (9)
Postmarket research (240)
Preclinical (396)
Prostate cancer (52)
Radiopharmaceuticals (32)
Rare diseases (101)
Real estate (210)
Recruiting (6)
Regulatory (1902)
Reports (14)
Research institute (113)
Resumes & cover letters (6)
RSV (6)
Schizophrenia (37)
Series A (13)
Series B (4)
Service/supplier (1)
Sickle cell disease (9)
Special edition (4)
Spinal muscular atrophy (36)
Sponsored (5)
Startups (145)
Stomach cancer (3)
Substance use disorders (1)
Supply chain (10)
Tariffs (4)
The Weekly (4)
Vaccines (73)
Venture capital (7)
Weight loss (56)
Women's health (14)
Worklife (2)
Date
Today (6)
Last 7 days (55)
Last 30 days (177)
Last 365 days (3554)
2026 (2619)
2025 (3361)
2024 (3586)
2023 (3991)
2022 (4465)
2021 (4842)
2020 (4028)
2019 (3244)
2018 (2400)
2017 (2231)
2016 (1669)
2015 (2269)
2014 (1503)
2013 (957)
2012 (1118)
2011 (1246)
2010 (1110)
Location
Africa (62)
Alabama (6)
Arizona (29)
Asia (2728)
Australia (325)
California (1553)
Canada (403)
China (173)
Colorado (56)
Connecticut (62)
Delaware (89)
Europe (11068)
Florida (229)
Georgia (51)
Hawaii (1)
Idaho (3)
Illinois (129)
India (13)
Indiana (88)
Japan (97)
Kansas (11)
Kentucky (6)
Louisiana (11)
Maine (11)
Maryland (199)
Massachusetts (961)
Michigan (36)
Minnesota (76)
Missouri (14)
Montana (3)
Nebraska (1)
Nevada (28)
New Hampshire (11)
New Jersey (644)
New York (379)
North Carolina (192)
Northern California (833)
Ohio (35)
Pennsylvania (411)
Puerto Rico (1)
Rhode Island (1)
South America (95)
South Carolina (4)
Southern California (654)
Tennessee (17)
Texas (173)
United States (5517)
Utah (53)
Virginia (36)
Washington D.C. (2)
Washington State (111)
Wisconsin (14)
50,149 Results for "41".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Global Concierge Medicine Market Size to Reach USD 41.37 Billion by 2035 Driven by Telehealth and AI-Powered Preventive Care
June 4, 2026
·
1 min read
Press Releases
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
August 13, 2026
·
19 min read
Press Releases
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
August 18, 2026
·
6 min read
Press Releases
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
August 14, 2026
·
4 min read
Deals
Angelini inks $4.1B Catalyst buy to enter US rare disease market
Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.
May 7, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
July 16, 2026
·
5 min read
Press Releases
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
July 24, 2026
·
6 min read
Press Releases
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
March 12, 2026
·
16 min read
Press Releases
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
May 14, 2026
·
14 min read
Press Releases
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
April 6, 2026
·
2 min read
1 of 5,015
Next
